BioCentury | May 26, 2020
Distillery Therapeutics

Blocking flu with phage capsid nanoparticles

DISEASE CATEGORY: Infectious disease INDICATION: Influenza virus Nanoparticles derived from phage capsids could prevent influenza infection by preventing HA-mediated viral entry. The nanoparticles comprise icosahedral bacteriophage capsid proteins conjugated to mono-ethylene glycol-linked sialic acid, which...
BioCentury | Apr 3, 2020
Product Development

COVID-19 roundup: Amgen taps Adaptive as its antibody therapeutic partner; plus Alnylam-Vir’s siRNA targets, Ansun’s data and more

Amgen entered the race to develop an antibody-based COVID-19 therapy Thursday, partnering with Adaptive Biotechnologies to screen for neutralizing mAbs. The day also saw Alnylam and Vir name the first targets from their siRNA partnership...
BioCentury | Mar 30, 2020
Finance

ElevateBio raises $170M, plans additions to portfolio with six clinical programs by 2021

...position. That company has begun a Phase I trial of a T cell therapy targeting HMHA1...
...in May 2019 (see “Creating A Portfolio With $150M” ). Targets HMHA1 (HA-1; HLA-HA1) - Histocompatibility minor HA-1 Paul...
BioCentury | Mar 20, 2020
Translation in Brief

Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar

Gates Foundation grants Vaxxas $5M for low-dose vaccine patch Vaxxas Pty. Ltd. received a $5 million grant Tuesday from the Bill and Melinda Gates Foundation to develop its high-density microarray patch (HD-MAP) to deliver vaccines....
BioCentury | Jan 17, 2020
Preclinical News

Jan 16 Preclinical Quick Takes: Deerfield's Orchard partners with Yeda; Acuitas-Penn flu vaccine in newborns; plus Regeneron, Genentech-Gladstone and Banyan

Deerfield forms Orchard Innovations in Yeda collaboration on translation Deerfield Management Co. launched Orchard Innovations LLC to pursue translational R&D derived from Weizmann Institute of Science research. Yeda Research and Development Co. Ltd., Weizmann’s commercial...
BioCentury | Nov 5, 2019
Company News

Ervaxx debuts with a new source of neoantigens

Ervaxx Ltd. emerged from stealth on Tuesday with £13 million ($16.8 million) from SV Health Investors and a platform for discovering and validating a new type of neoantigen present in the dark matter of the...
BioCentury | Oct 1, 2019
Company News

ElevateBio launches HighPassBio with TCR immunotherapy focus

...of the TCR therapy in a Blood paper published in January 2018. The compound targets HMHA1...
...Following HSCT, the donor’s immune system is intolerant to HMHA1 mismatch; thus, T cells from HMHA1-negative...
...I A 020; HMHA1 (HA-1; HLA-HA1) - Histocompatibility minor HA-1 Elizabeth S. Eaton, Staff Writer ElevateBio LLC Histocompatibility minor HA-1 (HMHA1) (HA-1) (HLA-HA1) Major...
BioCentury | Aug 30, 2019
Clinical News

Aug. 30 Clinical Quick Takes: Pharnext falls on FDA request for second Phase III study, plus Genentech, Novartis and Seqirus

Pharnext shares sag on regulatory slowdown Shares of Pharnext S.A. (Euronext:ALPHA) lost €4.99 (41%) to €7.16 on Friday after the company said FDA advised it to conduct a second Phase III study of PXT3003 prior...
BioCentury | Jul 25, 2019
Product Development

The universe of universal flu vaccines

With at least 10 flu vaccines in the clinic that could confer protection against a wide range of strains, dispensing with the yearly seasonal vaccine may be in reach. Currently, seasonal flu vaccines consist of...
BioCentury | Jul 9, 2019
Finance

Revolution raises $100M to build out Ras pipeline, explore SHP-2 combos

Following this year’s ASCO fervor around KRAS inhibitors, Revolution Medicines has raised $100 million in a series C round to advance its portfolio of Ras pathway inhibitors, including its own KRAS G12C inhibitor. The financing,...
Items per page:
1 - 10 of 366